dengue vaccine – pharmaceutical daily

February 27, 2024 Off

Akeada, Biological E. Limited in partnership to hasten access to dengue vaccine

A strategic partnership between Akeada and Biological E. Limited aims to hasten access to QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs) for National Immunization Programs by 2030. MDVs offer cost and logistical benefits, with BE aiming for a manufacturing capacity of 50 million doses yearly to support Takeda’s goal of 100 million doses annually within the decade.

November 6, 2019 Off

Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure

By BusinessWire

− New England Journal of Medicine publishes primary endpoint analysis from ongoing Phase 3 study of Takeda’s dengue vaccine candidate…

October 20, 2016 Off

Sun Pharma and ICGEB collaboration for development of a dengue vaccine

By Dino Mustafić

International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma have announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans.